TGF-β1 Inhibition, Cytokine Modulation, and Clinical Response to Seleno-L-Methionine Plus Axitinib and Pembrolizumab in Treatment-Naïve Clear Cell Renal Cell Carcinoma
International Journal of Molecular Sciences · 02.11.2026 · 27 (21) · 9825
DOI: 10.3390/ijms27219825 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.11.2026. Verfasst von Matthew R Kroll und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA. Hauptthemen laut MEDLINE: Axitinib, Antibodies, Monoclonal, Humanized, Carcinoma, Renal Cell, Transforming Growth Factor beta1. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Oncology, Pfizer.
Abstract (Originalsprache)
Metastatic clear cell renal cell carcinoma (ccRCC) remains largely incurable, and the efficacy of pembrolizumab plus axitinib may be limited by hypoxia-associated signaling, immunosuppressive cytokines, and metabolic reprogramming involving the TGF-β1/HIF axis. Seleno-L-methionine (SLM) is a pharmacologic inhibitor of this axis and its downstream effectors, including PD-L1 and VEGF. In a phase I/II pilot study (ClinicalTrials.gov NCT05363631), patients with newly diagnosed metastatic ccRCC received SLM twice daily for 14 days, then once daily with standard-dose axitinib; pembrolizumab was added on day 15. Endpoints included circulating (plasma) TGF-β1, plasma selenium, circulating cytokines, efficacy, and safety. Twelve patients were treated and evaluable for safety (six at 5000 µg, six at 6000 µg SLM); ten were evaluable for response. The objective response rate was 70% (complete response 40%, partial response 30%). Of the four patients with CR, two had favorable and two had intermediate International Metastatic Renal Cell Carcinoma Database Consortium disease. Grade 3 hypertension was documented in 58.3%, about twice the pivotal-trial rate, without treatment discontinuations or new toxicities. SLM increased plasma selenium and produced time-dependent inhibition of TGF-β1 and modulation of immune-related cytokines (CXCL13, IFN-γ, TNF-α, IL-6, IL-8). In this pilot study, SLM combined with axitinib and pembrolizumab showed time-dependent TGF-β1 inhibition, cytokine modulation, and encouraging antitumor activity without treatment-limiting toxicity, supporting further investigation of SLM for targeting the TGF-β1/HIF-driven immunosuppressive microenvironment in ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
- Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
- Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
ORCID-Profile: Matthew R Kroll, Yousef Zakharia, Vitor Fiorin de Vasconcellos, John M Rieth, Mariana Pilon Capella
Förderung
- Pfizer Oncology
- Pfizer
Zitieren
APA
Kroll, M. R., Zakharia, Y., Maciel Barbosa, F., Fiorin de Vasconcellos, V., Rieth, J. M., Milhem, M., Capella, M. P., & Rustum, Y. M. (2026). TGF-β1 Inhibition, Cytokine Modulation, and Clinical Response to Seleno-L-Methionine Plus Axitinib and Pembrolizumab in Treatment-Naïve Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences, 27(21), 9825. https://doi.org/10.3390/ijms27219825
Vancouver
Kroll MR, Zakharia Y, Maciel Barbosa F, Fiorin de Vasconcellos V, Rieth JM, Milhem M, et al. TGF-β1 Inhibition, Cytokine Modulation, and Clinical Response to Seleno-L-Methionine Plus Axitinib and Pembrolizumab in Treatment-Naïve Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences. 2026;27(21):9825. doi:10.3390/ijms27219825
BibTeX
@article{Kroll2026,
author = {Kroll, Matthew R and Zakharia, Yousef and Maciel Barbosa, Fernando and Fiorin de Vasconcellos, Vitor and Rieth, John M and Milhem, Mohammed and Capella, Mariana Pilon and Rustum, Youcef M},
title = {TGF-β1 Inhibition, Cytokine Modulation, and Clinical Response to Seleno-L-Methionine Plus Axitinib and Pembrolizumab in Treatment-Naïve Clear Cell Renal Cell Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9825},
doi = {10.3390/ijms27219825}
}
EUVIMED